EUVIMEDEUVIMED entdecken
Crossref

Relaxin‐2 mitigates the interaction between monocytes and endothelial cells by suppressing Egr‐1

Jing Bai iD, Hui Zhou

Fundamental & Clinical Pharmacology · 2025

DOI: 10.1111/fcp.70007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Jing Bai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Relaxin, Endothelial Cells, Monocytes, Early Growth Response Protein 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Renmin Hospital of Wuhan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

An overproduction of oxidized low‐density lipoprotein (ox‐LDL) can lead to vascular endothelial dysfunction. Relaxin‐2, a novel peptide hormone, exhibits various biological functions within the cardiovascular system. However, the effects of Relaxin‐2 in atherosclerosis (AS) are underreported.

Objectives

We aimed to investigate the regulatory role of Relaxin‐2 in the endothelial function of human aortic endothelial cells (HAECs) upon ox‐LDL stimulation.

Methods

HAECs were stimulated with ox‐LDL (100 mg/l) and rhRelaxin‐2 (25, 50 nM) for 24 h. Multiple techniques, including real‐time PCR, Western blot analysis, ELISA, and Calcein AM staining, were applied.

Results

Treatment with human recombinant (rh) Relaxin‐2 decreased lectin‐like ox‐LDL receptor 1 (LOX‐1), a primary receptor for ox‐LDL, in HAECs. rhRelaxin‐2 also reduced the ox‐LDL‐induced expression of pro‐inflammatory mediators such as interleukin 6 (IL‐6), tumor necrosis factor‐α (TNF‐α), and monocyte chemoattractant protein‐1 (MCP‐1). Additionally, we observed increased expression of cyclooxygenase‐2 (COX‐2), prostaglandin E2 (PGE2), and high mobility group protein B1 (HMGB‐1) in ox‐LDL‐challenged HAECs, which was diminished by rhRelaxin‐2. Significantly, the heightened expression of intercellular cell adhesion molecule‐1 (ICAM‐1) and E‐selectin in ox‐LDL‐stimulated HAECs was mitigated by rhRelaxin‐2. Consequently, rhRelaxin‐2 alleviated the attachment of THP‐1 cells to HAECs in a dose‐dependent manner. Mechanistically, we found that rhRelaxin‐2 inhibited the expression of Egr‐1, a central mediator of endothelial inflammation. Furthermore, overexpression of Egr‐1 was found to negate the beneficial effects of rhRelaxin‐2, suggesting that these effects are mediated by the suppression of Egr‐1.

Conclusion

Our findings propose a novel therapeutic approach with rhRelaxin‐2 for patients with atherosclerosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RelaxinEndothelial CellsMonocytesEarly Growth Response Protein 1HumansLipoproteins, LDLAtherosclerosisCells, CulturedRecombinant ProteinsScavenger Receptors, Class EAorta

Stichwörter der Autor:innen

Egr‐1Relaxin‐2atherosclerosisendothelial cellsox‐LDL

Substanzen

Relaxinoxidized low density lipoproteinLipoproteins, LDLRLN2 protein, humanEarly Growth Response Protein 1EGR1 protein, humanRecombinant ProteinsScavenger Receptors, Class EOLR1 protein, human

Autor:innen und Institutionen

  • Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
  • Department of Ultrasound, Wuhan Prevention and Treatment Center for Occupational Diseases, Wuhan, China.

ORCID-Profile: Jing Bai

Förderung

  • Renmin Hospital of Wuhan University

Zitieren

APA

Bai, J., & Zhou, H. (2025). Relaxin‐2 mitigates the interaction between monocytes and endothelial cells by suppressing Egr‐1. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70007

Vancouver

Bai J, Zhou H. Relaxin‐2 mitigates the interaction between monocytes and endothelial cells by suppressing Egr‐1. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.70007

BibTeX
@article{Bai2025,
  author = {Bai, Jing and Zhou, Hui},
  title = {Relaxin‐2 mitigates the interaction between monocytes and endothelial cells by suppressing Egr‐1},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/fcp.70007}
}
Kostenlos starten →